Share on LinkedInShare on LinkedIn

ARTICLE · 17 MARCH 2025

Federal Circuit Clarifies Anticipation Analysis For Product-By-Process Claims

Sheppard
Sheppard
Contributor
Sheppard

Sheppard

Businesses turn to Sheppard to deliver sophisticated counsel to help clients move ahead. With more...

View firm profile
Explore more from Sheppard

In Restem, LLC v. Jadi Cell, LLC, No. 2023-2054 (Fed. Cir. Mar. 13, 2025), the Federal Circuit upheld the Patent Trial and Appeal Board's decision holding that U.S. Patent No. 9,803,176 ("the '176 patent").

United StatesIntellectual Property

In Restem, LLC v. Jadi Cell, LLC, No. 2023-2054 (Fed. Cir. Mar. 13, 2025), the Federal Circuit upheld the Patent Trial and Appeal Board's decision holding that U.S. Patent No. 9,803,176 ("the '176 patent") was not inherently anticipated by a prior art process, because the prior art process did not inevitably result in the claimed cell marker expression profile.

Background

The '176 patent is directed to stem cells with specific cell markers obtained from the subepithelial layer of mammalian umbilical cord tissue. The independent claim at issue was drafted as a product-by-process claim that prepares an "isolated cell" with two steps: (1) placing the SL in direct contact with a tissue culture growth substrate and (2) culturing the SL. The claim also requires that the isolated cell express certain cell markers and not express other cell markers ("non-expression limitations").

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from